Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline H…

Introduction: We investigated the effect of baseline BMI on treatment with dulaglutide and active comparators in patients with T2DM with baseline HbA1c ≥7.5% (AWARD 1 – 5). The National Institute for Health and Care Excellence (NICE) recommends HbA1c ≥7.5% for initiation of GLP-1RA therapy. Methods: Post-hoc, by-study analyses of change in HbA1c and bodyweight in patients receiving once-weekly dulaglutide 1.5 mg (n = 954) or 0.75 mg (n = 943), exenatide (n = 165), insulin glargine (n = 432), metformin (n = 126) or sitagliptin (n = 224) at 26 weeks. Results: Across 5 studies, ranges of least squares mean (LSM; st…